Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for Anhedonia in Mood Disorders
NCT03915613Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intranasal insulin in major depressive disorder (MDD), bipolar disorder (BD) and anhedonia ((none)) (2 arms), sponsored by University Health Network. Primary endpoint: Effort-Expenditure for Rewards Task at 2 weeks. Started Oct 2021; status: recruiting.
02
Drugs
intranasal insulin
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)anhedonia ((none))
Beyond the preview
Go deeper on NCT03915613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915613.